

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.9962 - MYLAN / ASPEN'S EU THROMBOSIS BUSINESS

SECTION 1.2

Description of the concentration

1. This notification relates to the proposed concentration pursuant to Article 4 of Council Regulation 139/2004 between Mylan and a subset of Aspen's antithrombotic products in the EEA.
2. The business activities of the undertakings concerned are:
 - Mylan develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals in addition to OTC and consumer healthcare products.
 - The Target comprises certain commercialization rights and related intellectual property relating to the following Aspen antithrombotic products in the EEA: nadroparin (Fraxiparine and Fraxodi), fondaparinux (Arixtra), certoparin (Mono-Embolex) and danaparoid (Orgaran). These are injectable products used for the treatment and prevention of blood clots.